NASDAQ:BOLT Bolt Biotherapeutics Q3 2026 Earnings Date & Estimates $6.38 -0.16 (-2.45%) Closing price 04:00 PM EasternExtended Trading$6.43 +0.05 (+0.77%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bolt Biotherapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Bolt Biotherapeutics in Q3 2026Bolt Biotherapeutics is expected to post earnings of -$3.68 per share on revenue of $450 thousand. In the same quarter a year earlier Bolt Biotherapeutics reported -$3.72 per share on revenue of $2.17 million. Bolt Biotherapeutics last reported on August 11, 2026, posting -$4.57 per share and missing the -$3.39 consensus estimate. Bolt Biotherapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$3.68Expected Revenue$450 thousandPrior-Year EPS-$3.72Prior-Year Revenue$2.17 millionExpected Revenue Growth-79.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$4.57 (Missed by -$1.18)Last Quarter Revenue$10 thousandEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Bolt Biotherapeutics Q3 2026 Earnings FAQ When does Bolt Biotherapeutics report Q3 2026 earnings? Bolt Biotherapeutics (NASDAQ:BOLT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Bolt Biotherapeutics' Q3 2026 earnings call? Bolt Biotherapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Bolt Biotherapeutics? Analysts expect Bolt Biotherapeutics to post earnings of -$3.68 per share for Q3 2026. How much revenue is Bolt Biotherapeutics expected to report? The consensus revenue estimate for Bolt Biotherapeutics is $450 thousand for Q3 2026. Bolt Biotherapeutics Earnings HeadlinesINVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?November 4 at 8:16 AM | globenewswire.comBolt Biotherapeutics to Participate in Upcoming ConferencesNovember 3 at 8:00 AM | globenewswire.comWhy Iran May Only Be the First MoveTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.November 5 at 1:00 AM | Behind the Markets (Ad)Bolt Biotherapeutics consensus price target increased by 1,400% to $76.50November 2 at 8:42 PM | msn.comBolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks TranscriptOctober 26, 2026 | seekingalpha.comTranscript : Bolt Biotherapeutics, Inc., Prana Therapies, Inc. - M&A CallOctober 26, 2026 | marketscreener.comMSee More Bolt Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email. Email Address About Bolt BiotherapeuticsBolt Biotherapeutics (NASDAQ:BOLT) is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response. The company has also pursued myeloid cell engager therapies designed to activate macrophages and other immune cells against cancer. Its development programs have included BDC-1001, an investigational HER2-targeted ISAC evaluated in patients with HER2-expressing solid tumors, and BDC-3042, an investigational myeloid engager intended for use in combination with other cancer immunotherapies. Bolt Biotherapeutics was founded in 2015 and is headquartered in Redwood City, California. Its programs have been evaluated through clinical studies involving patients with advanced solid tumors.View Bolt Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
